Cerus (STU:CU2) Insider Ownership : 0.00 % (As of May. 25, 2024)

View and export this data going back to . Start your Free Trial

What is Cerus Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cerus's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cerus's Institutional Ownership is 55.27%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cerus's Float Percentage Of Total Shares Outstanding is 74.80%.

Cerus Insider Ownership Historical Data

The historical data trend for Cerus's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Insider Ownership Chart

Cerus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Insider Ownership

Get a 7-Day Free Trial

Cerus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Insider Ownership	Get a 7-Day Free Trial															-	-	-	-	-

Cerus Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Cerus (STU:CU2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (STU:CU2) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

CERS:USA

Address

1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520

Website

http://www.cerus.com

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Cerus (STU:CU2) Headlines

No Headlines